Abstract
This study was designed to evaluate the effects of BoxA on allergic rhinitis (AR). Ovalbumin (OVA)-induced AR mice model was employed and BoxA was administered to AR mice. AR symptoms, levels of cytokines and chemokines, and the expression of high mobility group box 1 (HMGB1), TLR2, and TLR4 were measured. BoxA treatment significantly ameliorated AR symptoms, decreased level of histamine, OVA-specific antibodies, suppressed the infiltration of immune cells in nasal tissues, inhibited the expression of IL-4, IL-6, IL-5, TNF-α, IL-13, IL-17, IL-2 while promoting the expression of IL-10, suppressed the expression of HMGB1, TLR2, and TLR4 in AR mice. BoxA ameliorated allergic rhinitis in mice by inhibiting HMGB1.
Author contributions
Liyan Yue, Jinhui Dong, Jianxing Wang, Xiaoyan Yin, Xiumin Ren, Ou Xu, and Chunguang Shan: data collection and manuscript writing. Liyan Yue, Jinhui Dong, Jianxing Wang, Xiaoyan Yin, Xiumin Ren, Ou Xu, and Chunguang Shan: data collection and analysis. Liyan Yue and Jinhui Dong: project development and manuscript writing.
Disclosure statement
The authors declare that they have no conflict of interest.
Ethical approval
The study was approved by the ethics committee of the Second Hospital of Hebei Medical University.
Data availability statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.